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Background: Fulminant hepatitis and biliary atresia are serious problems and their causes have not been ex-
plained well. We investigated whether or not erythrovirus B19 is a candidate etiologic agent in such liver disease 
patients who had undergone liver transplantation. 
Methods: Liver tissues from 47 patients consisted of 28 fulminant hepatitis and 19 biliary atresia were examined 
to detect B19 genes by PCR and further analyzed their genomic characterization. 
Results: B19 DNA was detected by nested PCR in 10 of 28 cases (35.7%) livers in the fulminant hepatitis group 
and 7 of 19 (36.8%) livers in the biliary atresia group, respectively (statistically not significant). Importantly, 
among the 8 hepatic B19 DNA-positive patients who had paired samples of liver and serum, the serum B19 ge-
nome was detectable in only one case. B19 mRNA was identified in all of 10 fulminant hepatitis cases with he-
patic B19 DNA, but only 1 out of 7 (14.3%) cases in biliary atresia tested. Furthermore, we obtained ten isolates 
having the B19 genome with nearly full-length sequences. Interestingly, phylogenetic analysis based on the NS1 
gene revealed three different clusters: two for isolates from fulminant hepatitis and the other for isolates from 
biliary atresia. 
Conclusions: Our results presented here suggested that B19 may be an etiologic agent of fulminant hepatitis. 
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1.  Introduction 
Erythrovirus (formally parvovirus) B19 (B19) 
causes a wide range of diseases in humans. B19 is a 
currently the only accepted member of the Erythrovi-
rus genus and the only erythrovirus known to be 
pathogenic in humans. Several workers reported cases 
of children with fulminant or acute hepatitis with 
acute B19 infection and suggested that B19 could be 
the cause of the hepatitis [1-3]. Their diagnosis was 
based on the detection of the serum B19 DNA by PCR 
assay. However, the cause of fulminant hepatitis and 
biliary atresia in many patients is unexplained and 
this is a serious issue, especially in newborns and in-
fants. More than 80% of these cases ultimately require 
liver transplantation or die of hepatic failure. B19 has 
been proposed as the cause of the fulminant hepatic 
failure in patients with or without aplastic anemia, on 
the basis of the presence of B19 DNA in liver speci-
mens. However, the mechanism of liver damage by 
B19 infection remains conjectural. An immunologi-
cally-mediated mechanism of B19-induced hepatocyte 
destruction has been postulated, but not documented. 
Thus, there could be an unsuspected cofactor that is 
associated with B19 infection and is deleterious to the 
liver. To address these important issues, we conducted 
a molecular characterization of B19 genomes isolated 
from patients with fulminant hepatitis and biliary 
atresia. 
2.  Materials and Methods 
Patients: We compared 2 different groups con-
sisted with 47 Japanese patients (aged from newborns 
to 66 years old; 24 males and 23 females). Group A 
consisted of 28 patients with fulminant hepatitis (14 
males and 14 females; 9 infants less than one year old, 
8 children 1-10 years old, 3 adolescents 11-20 years old 
and 8 adults over 21 years old). On the other hand, 
group B consisted of 19 patients with biliary atresia; 7 
males and 12 females; 4 infants less than one year old, 
10 children 1-10 years old, 4 adolescents 11-20 years 
old and one adult over 21 years old). All patients ex-Int. J. Med. Sci. 2007, 4 
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amined had no evidence of hepatitis virus infections 
and diagnosed as non-B, non-C hepatitis. Most of the 
patients tested underwent living-donor liver trans-
plantation at Kyoto University Hospital from 1994 to 
2000. Majority of patients had history of blood trans-
fusion or blood product infusion in their course of 
treatment. The liver tissues and serum samples from 
recipients obtained at operation stored at -80°C until 
used. Informed consent for participation in this study 
was obtained from each individual. 
Nucleic acid extraction, PCR and sequencing 
analysis: Nucleic acids (DNA/RNA) were extracted 
from frozen liver tissues and serum using SepaGene 
RV-R Kit (Sanko-Junyaku, Tokyo, Japan). The result-
ing pellet was resuspended in 100 µl RNase-free water, 
following the manufacturer’s instruction. B19 DNA 
was screened by nested PCR using primers designed 
from VP1 region; PV1 (sense, 5’-GCT GTT AAG GAT 
GTT ACA GA-3’, nucleotide (nt) 3520-3521) and PV1R 
(antisense, 5’-GGA TCC GTA TAA GGG ATT GT-3’, 
nt 3882-3901) for the 1st PCR and PV2 (sense, 5’-CAG 
GTT ACT GAC AGC ACT AC-3’, nt 3541-3560) and 
PV2R (antisense, 5’-TGT TGA CTG CAG CCC TCT 
AA-3’, nt 3848-3867) for the 2nd PCR (Yoto et al., 1996). 
The sensitivity of this PCR assay allowed detection of 
as few as 10 copies of B19 genome. In addition, we 
sequenced the B19 isolates consisted of 4561 bp cov-
ering NS1, VP1 and VP2 regions obtained from liver 
tissues of patients. For this purpose, three overlapping 
PCR products (fragments A to C) were generated; for 
fragment A (1944 bp), PV3 (sense, 5'-TTT CCC GCC 
TTA TGC AAA TGG GCA G-3', nt 393-417) and PV5R 
(antisense, 5’-AGC TCC CAC ATG GCA GCT AC-3’, 
nt 2533-2552) for the 1st PCR and PV4 (sense, 5'-TGT 
AAC GGT TAA AAT GGG CGG AGC G-3', nt 457-481) 
and PV6R (antisense, 5'- CCC CTT ACA CCG TCC 
CAC AC-3', nt 2382-2401) for the 2nd PCR; for frag-
ment B (1835 bp), PV5 (sense, 5'-GCA GCA GTG GTG 
GTG AAA GC-3', nt 2143-2162) and PV1R for the 1st 
PCR and PV6 (sense, 5'-GGC GCC TGG AAC ACT 
GAA AC-3', nt 2208-2227) and PV2R for the 2nd PCR; 
for fragment C (1297 bp), PV1 and PV3R (sense, 
5'-TAC AGT CTG GGT GGT ACT GGT GGG C-3', nt 
5010-5034) for the 1st PCR and PV2 and PV4R (an-
tisense, 5'-CTG GTG GGC GTT TAG TTA CGC ATC 
C-3', nt 4994-5018). Nucleotide positions are based on 
B19-HV isolate (accession No. AF162273). The PCR 
was done with AmpliTaq Gold (Perkin Elmer, Nor-
walk, Conn.) and Blend-Taq-Plus DNA polymerase 
(TOYOBO Co., Tokyo, Japan). The amplicons were 
separated by 1% agarose gel electrophoresis and puri-
fied using the QIAquick gel extraction kit (Qiagen Inc., 
Chatsworth, Calif.). Recovered amplicons were sub-
jected to direct sequencing from both directions using 
the ABI PRISMTM Big Dye Terminator Cycle Se-
quencing Ready Reaction Kit (Perkin Elmer). Se-
quences of amplified DNA were determined using a 
sequencer (ABI model 373A; Applied Biosystems, 
Foster City, Calif.). Additionally, hepatitis A, B, C and 
E genomes were also determined by the nested PCR. 
Detection of B19 mRNA: The purified RNA ob-
tained from liver tissues as described above, was di-
gested by RQ I DNase (Promega Co., Madison, Wis.) 
to remove any DNA. B19 cDNA was synthesized from 
the pretreated RNA by reaction with 100 units of 
Moloney murine leukemia virus reverse transcriptase 
(Promega Co.) and PV1R antisense primer. The cDNA 
obtained was subjected to nested PCR amplification. 
Phylogenetic analysis: Characterization of B19 
isolates was examined by the phylogenetic analysis as 
described previously [4]. The data were analyzed us-
ing a standard statistical software package (Stat View; 
Brain Power Inc., Calabases, CA, U.S.A.).   
Statistic analyses: Statistic analyses were per-
formed by the chi-square test. A difference with a P 
value of less than 0.05 was considered significant. 
3.  Results 
B19 DNA in liver tissues was detected in 10 of 28 
(35.7%) patients with fulminant hepatitis and 7 of 19 
(36.8%) patients with BA, respectively (statistically not 
significant). Except for two infants with fulminant 
hepatitis who were HBV DNA-positive, all cases 
tested were negative for HAV RNA, HCV RNA and 
HEV RNA. Importantly, among the hepatic B19 
DNA-positive 8 patients who had paired samples of 
liver tissues and serum, the serum B19 sequence was 
detectable in only one case (Table 1). 
Table 1. Comparison of B19 DNA detection between serum 
and liver tissue 
 
 
To determine the form of viral replication, the 
presence of B19 mRNA in the liver tissue was exam-
ined. The results showed that B19 mRNA was present 
in all cases with fulminant hepatitis to be hepatic 
B19-positive, but only 1 of 7 (14.3%) cases in biliary 
atresia tested. Amplification of B19 DNA did not take 
place in the absence of reverse transcriptase, indicat-
ing minimal DNA contamination. 
In addition to the above-described examinations, 
to characterize the B19 genomes, we obtained 14 iso-
lates of the B19 genome (10 isolates with nearly 
full-length sequences (4561 bp) that covered the com-
plete genes of NS1, VP1 and VP2 and 4 isolates with 
only one short sequence in the NS1). All B19 isolates 
showed an overall identity of 98% at the nt level 
among each isolate with 4561 bp recovered in this 
study and to prototypes of B19 HV (F162273) and B19 Int. J. Med. Sci. 2007, 4 
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Au (M13178), and an identity of 87% to 
the B19 V9 isolate (AY083234). Interest-
ingly, phylogenetic analysis based on the 
NS1 gene revealed three different clus-
ters: two (genotypes 1 and 3) for isolates 
from fulminant hepatitis and the other 
(genotype 2) for isolates from biliary 
atresia (Fig. 1). Among each genotype, 
specific sites of the deduced amino acid 
sequence change were identified in the 
NS1 gene (Fig. 2). In 7 isolates belonging 
to group 2, the amino acid at position 181 
and 201 showed methionine and aspartic 
acid, respectively. Interestingly, aspartic 
acid substitution in 201 localized within 
the putative B cell epitope. Furthermore, 
in 5 out of 6 isolates belonging to group 3, 
the amino acid at position 183 substi-
tuted to alanine. 
 
   
Figure 1. Phylogram generated by neighbor-joining analysis of genetic distances in the NS1 region of erythrovirus B19. The per-
centage of bootstrap replicates supporting these branches is shown. FH=fulminant hepatitis, BA=biliary atresia. 
 
 
Figure 2. Alignment of amino acid sequences (upper) and nucleic acid sequences (lower) in the NS1 region of erythrovirus B19. Dot 
(.) indicate amino acids identical to the top sequence. B cell epitope region indicated by box.  Int. J. Med. Sci. 2007, 4 
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Nucleotide sequence data reported are available 
in the DDBJ/GenBank/EMBL database under the ac-
cession numbers: AB126262 for B19-AN23, AB126263 
for B19-AN28, AB126264 for B19-AN30, AB126265 for 
B19-AN34, AB126266 for B19-AN40, AB126267 for 
B19-AN41, AB126268 for B19-AN56, AB126269 for 
B19-AN66, AB126270 for B19-AN85 and AB126271 for 
B19-AN87. 
4.  Discussion 
The etiology of hepatitis remains obscure in 
3-10% of cases in Europe [5] and the United States [6] 
and up to 30% of cases in Asia [7, 8]. Particularly, the 
cause of fulminant hepatitis in children is unexplained 
in up to 50% of cases in our hospital. Once 
well-known hepatotropic agents and metabolic, toxic, 
and immunological causes have been excluded, an 
infectious origin remains a possibility. Opportunistic 
infections may be the cause of fulminant hepatitis in 
immunocompromised patients. 
On the other hand, the concept that biliary atresia 
consists of two major types based on the clinical as-
pects has been accepted [9, 10]. One is the fetal, em-
bryonic or prenatal type, and the other is the acquired 
or perinatal type. The perinatal type is believed to ac-
count for 70-80% of all biliary atresia. The etiology of 
biliary atresia has remained obscure. Two hypotheses 
have been put forward. The first is called the ductal 
plate malformation theory, which assumes a congeni-
tal anomaly of the intrahepatic bile trees. According to 
the other theory, the progressive occlusion of the ex-
trahepatic bile duct is probably triggered by viral in-
fection and worsened by the subsequent immunopa-
thological process. Reovirus, rotavirus [11, 12], cy-
tomegalovirus [13, 14] and others have been proposed 
as likely causative viruses, but no clear relation has 
been found. To the best of our knowledge, there are 
only a few reports [1, 15, 16] on the analysis of viral 
infections based on direct detection of viral genomes 
from liver tissues. 
B19 was discovered serendipitously in the sera of 
normal blood bank donors while screening for the 
hepatitis B virus. B19, a member of the family Parvo-
viridae, subfamily Parvovirinae, genus Erythrovirus, is 
a small single stranded DNA virus. B19 is a patho-
genic virus that is widely distributed in human popu-
lations. This virus is responsible for various clinical 
manifestations including erythema infectiosum in 
children, polyarthropathy syndrome in adults, tran-
sient aplastic crisis inpatients with chronic anemia, 
persistent infections manifesting as chronic anemia in 
immunocompromised patients, transplant recipients, 
and hydrops fetalis and fetal death by intrauterine 
infection. Aplastic anemia, which occurs in 33% of 
children and 5% of adult patients who undergo or-
thotopic liver transplantation (OLT) for non-A, non-B, 
non-C fulminant hepatitis is pointed out as a compli-
cation with a high rate of mortality [17]. The cause of 
aplastic anemia after OLT may include factors such as 
posthepatitic aplasia, B19, and drugs. Langnas et al. [1] 
reported the possibility of B19 as the cause of non-A-C 
fulminant hepatitis-associated aplastic anemia. Actu-
ally, B19 may be an etiologic agent for hepati-
tis-associated aplastic anemia, because of the known 
tropism of B19 for erythroid precursors [18]. On the 
other hand, negative data are also present. Wong et al. 
[16] reported no association with fulminant hepatitis 
or hepatitis-associated aplastic anemia. Lee et al. [19] 
reported no evidence for hepatitis E or parvovirus B19 
infection in patients with acute liver failure. 
To investigate the possibility that B19 infection of 
the liver might cause fulminant hepatitis and biliary 
atresia, we conducted a study to obtain direct evi-
dence of a viral sequence in the liver from patients 
who underwent liver transplantation. In this retro-
spective study of 47 patients with liver diseases of 
unknown etiology, B19 DNA was detected in the liver 
obtained from 17 patients. We postulated that the vi-
rus might even be detected in liver that is serologically 
negative for the virus. In fact, our results showed that 
only one case was sero-positive for the B19 sequence 
among 8 cases with intrahepatic-B19 DNA. These re-
sults suggest that seronegativity for the B19 sequence 
does not exclude the existence of present infection of 
B19 within the liver. Similar finding was reported by 
Eis-Hubinger et al [20]. They showed B19 DNA is fre-
quently present in livers of anti-B19 seropositive 
adults suggesting persistence of B19 in the liver. Our 
results also indicate that direct detection of viral ge-
nomes in tissues by a highly sensitive method is as 
important as serology. In the present study, we found 
a high prevalence of B19 infection not only in fulmi-
nant hepatitis patients, but also in biliary atresia pa-
tients. However, all fulminant hepatitis patients in-
fected with B19 had the replicative form of B19 mRNA. 
While, low rate of B19 mRNA detection in biliary 
atresia patients who had intra-hepatic B19 DNA sug-
gested silent infection of B19. This suggests that B19 
may be a cause of severe hepatic diseases although 
this remains to be investigated. 
B19 has a genome length of 5.4 kb with hairpin 
structures at each extremity. B19 encodes three major 
viral proteins: VP1 and NP2, the viral capsid proteins, 
and NS1, a nonstructural protein. Both VP1 and VP2 
are derived from overlapping reading frames and 
share substantial amino acid sequences. NS1 is known 
to be implicated in viral replication, the activation of 
viral gene transcription, and target cell cytotoxicity 
[21-25]. Among the sequence records deposited in the 
database, only 16 isolates of B19 have been sequenced 
in the full or nearly full-genome so far. Here we re-
ported that the nearly full-length sequence of B19 was 
isolated from 10 patients with liver diseases. It is 
known that B19 has a genome length of 5.4 kb with 
hairpin structures at each extremity; in addition, a 
partial deletion and rearrangement of the sequence 
exist in the extremity regions. These findings indicate 
the difficulty in amplifying the sequences in these re-
gions. In our study, we attempted to amplify each ex-
tremity, but failed. Interestingly, phylogenetic analysis 
based on the NS1 gene revealed three different clus-
ters: two for isolates from fulminant hepatitis and the Int. J. Med. Sci. 2007, 4 
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other for isolates from biliary atresia cases. This find-
ing suggests the existence of genotypes. Viral geno-
type has diagnostic and clinical implications, includ-
ing use for assessing responses to anti-viral therapy 
and future vaccine development. The possibility that 
such variation is involved in the severity of associated 
liver disease, and that the difference between symp-
tomatic and asymptomatic infection, may also occur as 
well as HBV and HCV. Furthermore, among each 
genotype, specific sites of the deduced amino acid se-
quence change were identified in the NS1 gene. Clari-
fication of the relation between the genotypes or vari-
ants of B19 and its pathogenicity in hepatic failure in-
cluding hepatitis and biliary atresia is awaited with 
great interest. To solve these important issues, a geo-
graphical study of the B19 genomes and various dis-
eases including liver diseases in different countries is 
now planning and we shall report on further investi-
gations in the future. 
In conclusion, we found a high prevalence of B19 
infection in livers from patients with fulminant hepa-
titis and biliary atresia. Interestingly, all fulminant 
hepatitis patients infected with B19 had the replicative 
form of B19 mRNA. It is noteworthy that serum B19 
DNA was not detected in 7 of 8 cases that were he-
patic B19 DNA-positive. Phylogenetic analysis based 
on the NS1 gene revealed three different clusters. Our 
results presented here suggested that B19 may serve 
as an etiologic agent for severe hepatitis. 
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